Clinical Trials Logo

Bladder Neoplasms clinical trials

View clinical trials related to Bladder Neoplasms.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02900248 Terminated - Multiple Myeloma Clinical Trials

CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice

N1
Start date: October 2, 2017
Phase:
Study type: Observational [Patient Registry]

Registry participants with advanced malignancy or myelodysplasia will have a sample of their tumor or tissue analysed for genetic alterations using next generation sequencing (NGS) performed in a lab that has been certified to meet a high quality standard. Treatments and outcomes will be reported to the registry to allow further understanding of how genetic differences can lead to better diagnosis and treatments.

NCT ID: NCT00191477 Terminated - Bladder Neoplasms Clinical Trials

Instillation of Gemcitabine in Patients With Superficial Bladder Cancer

Start date: January 2004
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, placebo-controlled Phase 3 multicenter study to assess the efficacy and safety of intravesical instillation of gemcitabine versus placebo immediately after transurethral resection of the bladder tumor.

NCT ID: NCT00050687 Terminated - Multiple Myeloma Clinical Trials

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

Start date: June 2001
Phase: Phase 1/Phase 2
Study type: Interventional

This study will test the safety, tolerance, and efficacy of different doses of oral gallium maltolate. Patients will receive oral gallium maltolate twice daily for 28-consecutive days followed by 14 days off treatment. This dosing cycle will be repeated. Adverse effects will be assessed and the levels of gallium in serum will be measured. Any effect of the drug on the cancer and any improvement in cancer-related symptoms will also be measured.